Show Notes
Despite significant scientific progress in neuroscience, clinical trial success rates remain low. Complex diseases, evolving therapeutic approaches and challenges around endpoint selection continue to make development difficult.
As biomarkers, AI and precision medicine become increasingly integrated into clinical research, sponsors have new opportunities to strengthen study design, improve patient selection and make more informed development decisions throughout the clinical development journey.
This podcast explores: -Why endpoint selection remains one of the greatest challenges in neuroscience development -How biomarkers are improving trial design and earlier development decisions -The role of AI and precision medicine in advancing neuroscience research -Common pitfalls when transitioning from early-phase to pivotal studies -Why early regulatory engagement and integrated development strategies matter
More from Scrip Podcasts
Ahead of the awards presentation on Dec 2, the Scrip Awards podcast speaks to Mathai Mammen, CEO of Parabilis, one of the shortlisted companies for Biotech of The Year.
本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年10月16日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。
Join us for an audio catch-up on the major events in the global biopharma industry over the past week, as reported by Scrip’s global team, in this podcast version of Five Must-Know Things.
Join us for an audio catch-up on the major events in the global biopharma industry over the past week, as reported by Scrip’s global team, in this podcast version of Five Must-Know Things.
本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年10月9日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。本周内容包括：中国带来的竞争威胁；第三季度并购活动降温；新型肺炎球菌疫苗竞争者；西班牙生物技术公司的战略；以及盐野义制药20亿美元的收购案。